Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cervical Cancer, Breast Cancer, Contraceptive Usage, Sexually Transmitted Diseases
Interventions: SHE-WOMEN; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Human Immunodeficiency Virus, Mental Health
Interventions: D*STAR, D*HEALTH; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: SARS-CoV-2 Infection
Interventions: S-217622, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: Not listed
Enrollment: 3,701 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 95
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more

Conditions: HIV, Mental Health, Substance Use, STI
Interventions: Automated Messaging & Monitoring, Peer Support, Coaching; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 24 Years
Enrollment: 1,478 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • New Orleans, Louisiana

Conditions: Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
Interventions: Valacyclovir, Valganciclovir; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Skin Flora Infection
Interventions: IV Clear™ Dressing, Tegaderm CHG™, Silicone Vehicle Control Dressing; Device
Lead sponsor: Covalon Technologies Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Miamiville, Ohio

Conditions: Teen Pregnancy, Pregnancy in Adolescence, Teen Pregnancy Prevention, Pregnancy Prevention, Sexually Transmitted Diseases
Interventions: Future Foundation 2.0 PREIS Program; Behavioral
Lead sponsor: Metis Associates, Inc.; Industry
Eligibility: 10 Years to 14 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: East Point, Georgia

Conditions: HIV/AIDS
Interventions: Cabotegravir Injection; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Surgical Site Infection, Cesarean Section; Infection
Interventions: 2% Chlorhexidine gluconate with 70% alcohol, 4% Chlorhexidine Gluconate aqueous solution; Drug
Lead sponsor: Hyagriv Simhan; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions: Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV, STIs, STIs Prevention, HIV Prevention
Interventions: Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Clostridium Difficile Infection
Interventions: Oral Vancomycin, Placebo; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: COVID-19, SARS-CoV-2
Interventions: VYD222 (pemivibart), Normal saline; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Internet-based tailored prevention messages, Non-tailored messages; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID19
Interventions: RTB101, Placebo; Drug
Lead sponsor: Restorbio Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Middletown, Rhode Island

Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions: Sirolimus; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV-1-infection
Interventions: no intervention; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions: Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions: INNA-051, Placebo; Drug · Other
Lead sponsor: ENA Respiratory Pty Ltd; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Bethesda, Maryland • College Park, Maryland + 3 more

Conditions: Acute, Perforated Appendicitis
Interventions: Irrigation with PVI, Usual care; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Social Media Messages Intervention Group, Website Only Group; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Transgenderism, HIV Infections
Interventions: Transgender men's perspectives on HIV risk and HIV prevention interventions; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronavirus, Corona Virus Infection
Interventions: Group 1 HCQ, Group 2 Placebo; Drug
Lead sponsor: UnitedHealth Group; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

Sexual Health Empowerment for Women's Health

Digital Star: HIV Prevention for Youth in Mental Health Treatment

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Engaging Seronegative Youth to Optimize HIV Prevention Continuum

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

Antimicrobial Activity of IV Clear™ Dressing - Prevention of Antimicrobial Regrowth

Future Foundation 2.0 Personal Responsibility Education Innovative Strategies (PREIS) Program

Oregon PrEP at Home Study

Aqueous vs Alcohol Chlorhexidine Skin Preparation for Prevention of Cesarean Section Wound Infections

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Combatting HIV Or Other STIs Early (CHOOSE)

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

A Tailored Interactive Website for Promoting Condom Use Among Young Adults

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

Longer-Acting PrEP in Transgender and Gender Diverse Texans

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study

Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media

Transgender Men's Perspectives on HIV Risk and HIV Prevention Interventions

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine